Polo-like kinase, a novel marker for cellular proliferation

被引:0
|
作者
Yuan, JP
Horlin, A
Hock, B
Stutte, HJ
RubsamenWaigmann, H
Strebhardt, K
机构
[1] CHEMOTHERAPEUT FORSCHUNGSINST,D-60596 FRANKFURT,GERMANY
[2] UNIV FRANKFURT,SCH MED,DEPT PATHOL,D-60596 FRANKFURT,GERMANY
[3] PHARMA RES CTR,INST VIROL,D-42096 WUPPERTAL,GERMANY
来源
AMERICAN JOURNAL OF PATHOLOGY | 1997年 / 150卷 / 04期
关键词
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
PLK (polo-like kinase) belongs to a family of serine/threonine kinases and represents the human counterpart of polo in Drosophila melanogaster and of CDC5 in Saccharomyces cerevisiae. lt is strongly involved in spindle formation and chromosome segregation curing mitosis. We have shown previously that PLK mRNA expression correlates with the mitotic activity of cells and the prognosis of lung cancer patients. In this report, the level of PLK protein was analyzed using immunohistochemical techniques. PLK protein was found expressed in the nuclei of tumor cells from lung and breast cancer as well as in several tumor cell lines. Furthermore, in peripheral lymphocytes treated with phytobemagglutinin, elevated proliferative activity of the cells correlated with the up-regulation of PLK protein expression. In contrast, in U937 and HL-60 cells after induction of differentiation with phorbol ester, PLK immunostaining disappeared under conditions of terminal differentiation. Most of the PLK protein was found in the nucleus of proliferating cells with diffuse but distinct staining also in the cytoplasm. Taken together, high levels of PLK protein are associated with cellular proliferation. Combined with other proliferative and oncogene markers, PLK may be useful for improved prediction of the clinical prognosis of cancer patients and for early cancer diagnosis. Due to its activity late in the cell cycle, it may be a target for cancer chemotherapy.
引用
收藏
页码:1165 / 1172
页数:8
相关论文
共 50 条
  • [31] Investigation of the cellular determinants influencing the subcellular localization of human polo-like kinase 2
    Cizmecioglu, O
    Hoffmann, I
    EUROPEAN JOURNAL OF CELL BIOLOGY, 2005, 84 : 57 - 57
  • [32] Phosphopeptides with improved cellular uptake properties as ligands for the polo-box domain of polo-like kinase 1
    Richter, Susan
    Neundorf, Ines
    Loebner, Kristin
    Graeber, Martin
    Berg, Thorsten
    Bergmann, Ralf
    Steinbach, Joerg
    Pietzsch, Jens
    Wuest, Frank
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (16) : 4686 - 4689
  • [33] Identification of Novel Polo-like Kinase 1 Inhibitors by a Hybrid Virtual Screening
    Lu, Shuai
    Sun, Shan-Liang
    Liu, Hai-Chun
    Chen, Ya-Dong
    Yuan, Hao-Liang
    Gao, Yi-Ping
    Yang, Pei
    Lu, Tao
    CHEMICAL BIOLOGY & DRUG DESIGN, 2012, 80 (02) : 328 - 339
  • [34] Validation of Polo-like Kinase 1 as a novel therapeutic target in alveolar rhabdomyosarcoma
    Thalhammer, Verena
    Herrero-Martin, David
    Hecker, Regina
    Niggli, Felix K.
    Schafer, Beat W.
    CANCER RESEARCH, 2012, 72
  • [35] Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer
    Ahmad, N
    FASEB JOURNAL, 2004, 18 (01): : 5 - 7
  • [36] Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells
    Pezuk, Julia Alejandra
    Brassesco, Maria Sol
    Manzini Ramos, Priscila Maria
    Scrideli, Carlos Alberto
    Tone, Luiz Gonzaga
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2017, 17 (09) : 1278 - 1291
  • [37] Pan-cancer analysis of polo-like kinase family genes reveals polo-like kinase 1 as a novel oncogene in kidney renal papillary cell carcinoma
    Zhao, Guo
    Wang, Yuning
    Zhou, Jiawei
    Wang, Shuhang
    Li, Ning
    HELIYON, 2024, 10 (08)
  • [38] A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies
    T Ikezoe
    J Yang
    C Nishioka
    Y Takezaki
    T Tasaka
    K Togitani
    H P Koeffler
    A Yokoyama
    Leukemia, 2009, 23 : 1564 - 1576
  • [39] A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies
    Ikezoe, Takayuki
    Nishioka, Chie
    Yang, Jing
    Takezaki, Yuka
    Tasaka, Taizo
    Koeffler, Phillip
    Yokoyama, Akihito
    CANCER RESEARCH, 2009, 69
  • [40] A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies
    Ikezoe, T.
    Yang, J.
    Nishioka, C.
    Takezaki, Y.
    Tasaka, T.
    Togitani, K.
    Koeffler, H. P.
    Yokoyama, A.
    LEUKEMIA, 2009, 23 (09) : 1564 - 1576